Arena Pharmaceuticals, Inc.’s (NASDAQ:ARNA ) shares dropped 9.4% following news that its CEO Jack Lief, has sold around 40% of his stake in the company. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock performance was -5.29% in last session and finished the day at $5.01. Traded volume was 7.44million shares in the last session and the average volume of the stock remained 4.98million shares. The beta of the stock remained -0.41. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) insider ownership is 0.70%.

Bristol-Myers Squibb Co. (NYSE:BMY) announced that the Japanese Ministry of Health, Labor and Welfare has approved Daklinza (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), and Sunvepra (asunaprevir), a NS3/4A protease inhibitor, providing a new treatment that can lead to cure for many patients in Japan who currently have no treatment options. Bristol-Myers Squibb Co (NYSE:BMY) dropped -0.31 percent to $47.86 Tuesday on volume of 6.87million shares. The intra-day range of the stock was $47.34 to $47.89. Bristol-Myers Squibb Co (NYSE:BMY) has a market capitalization of $79.31billion.

Biotechs Gilead Sciences (NASDAQ:GILD) and Anika Therapeutics (NASDAQ:ANIK) are among just a few stocks in the Spotlight screen that are still hovering near buy points. Gilead Sciences, Inc. (NASDAQ:GILD)’s stock on July 08, 2014 reported a decrease of -0.11% to the closing price of $87.11. Its fifty two weeks range is $53.21 -$88.60. The total market capitalization recorded $133.77billion. The overall volume in the last trading session was 11.73million shares. In its share capital, GILD has 1.54billion outstanding shares.

TherapeuticsMD Inc (NYSEMKT:TXMD) climbed over 17 percent in the current trading session after FBR Capital Markets issued an “Outperform” rating for the  specialty pharmaceutical company with a price target of $34 per share for the stock, in a research report published yesterday. On Tuesday, shares of TherapeuticsMD Inc (NYSEMKT:TXMD) advanced 32.45% to close the day at $5.47. Company return on investment (ROI) is -47.20% and its monthly performance is recorded as 33.74%. TherapeuticsMD Inc (NYSEMKT:TXMD) quarterly revenue growth is 8.53%.

CRT Capital initiates Boston Scientific Corporation (NYSE:BSX) with a Buy and price target of $16 as co’s turnaround is tracking ahead of plan and should be reflected in shares over time. Firm expects stable 3-5% top line growth beginning this year, 10-12% eps growth based on 300bps of margin expansion by 2015 and 30-35% return of capital to shareholders. Boston Scientific Corporation (NYSE:BSX) stock performance was -0.15% in last session and finished the day at $13.00. Traded volume was 9.97million shares in the last session and the average volume of the stock remained 12.67million shares. The beta of the stock remained 1.09. Boston Scientific Corporation (NYSE:BSX) insider ownership is 0.20%.